Elutia Founder and CEO Offers Insight on Kilpatrick Townsend's Impactful Guidance

Kilpatrick Townsend is proud to have provided counsel to Elutia in its rebrand to reflect its strategic focus on drug eluting biomatrices.

Elutia Founder and CEO C. Randal Mills, Ph.D. says, “In September, our company accomplished three key milestones:
1) We rebranded as Elutia to reflect our strategic focus on drug eluting biomatrix technology,
2) sold our Orthobiologics Business Unit, and
3) closed a private placement for proceeds up to $26M.

Each of these major corporate events would not have been possible without the help from the dedicated team at Kilpatrick Townsend & Stockton LLP.

Led by Michael "Mick" Cochran, David M. Eaton, Agnes Trenche Mora, Catherine Zhu, and Paige Clifton, we received the highest level of legal support and counsel to help guide us through each of these complex announcements. I am personally appreciative of Kilpatrick's unparalleled commitment and professionalism. We look towards continuing our relationship as our company executes on future milestones.”